S
Steven Roels
Researcher at Foundation Medicine
Publications - 8
Citations - 3487
Steven Roels is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Exome & Cancer. The author has an hindex of 5, co-authored 7 publications receiving 2408 citations.
Papers
More filters
Journal ArticleDOI
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers,Caitlin F. Connelly,David Fabrizio,Siraj M. Ali,Riley Ennis,Alexa B. Schrock,Brittany Campbell,Adam Shlien,Juliann Chmielecki,Franklin W. Huang,Yuting He,James Sun,Uri Tabori,Mark Kennedy,Daniel S. Lieber,Steven Roels,Jared White,G. Otto,Jeffrey S. Ross,Levi A. Garraway,Levi A. Garraway,Vincent A. Miller,Phillip J. Stephens,Garrett M. Frampton +23 more
TL;DR: Measurements of TMB from comprehensive genomic profiling are strongly reflective of measurements from whole exome sequencing and model that below 0.5 Mb the variance in measurement increases significantly, demonstrating that many disease types have a substantial portion of patients with high TMB who might benefit from immunotherapy.
Journal ArticleDOI
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
Garrett M. Frampton,Siraj M. Ali,Margaret Rosenzweig,Juliann Chmielecki,Xinyuan Lu,Todd M. Bauer,Mikhail Akimov,Jose A. Bufill,Carrie B. Lee,David Jentz,Rick Hoover,Sai-Hong Ignatius Ou,Ravi Salgia,Tim Brennan,Zachary R. Chalmers,Savina Jaeger,Alan Huang,Julia A. Elvin,Rachel L. Erlich,Alex Fichtenholtz,Kyle Gowen,Joel R. Greenbowe,Adrienne Johnson,Depinder Khaira,Caitlin McMahon,Eric M. Sanford,Steven Roels,Jared White,Joel Greshock,Robert Schlegel,Doron Lipson,Roman Yelensky,Deborah Morosini,Jeffrey S. Ross,Eric A. Collisson,Malte Peters,Philip J. Stephens,Vincent A. Miller +37 more
TL;DR: Analysis of tumor genomic profiles from 38,028 patients is reported to identify 221 cases with METex14 mutations, including 126 distinct sequence variants, and identify a unique subset of patients likely to derive benefit from MET inhibitors.
Journal ArticleDOI
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
Jie He,Omar Abdel-Wahab,Michelle Nahas,Kai Wang,Raajit K. Rampal,Andrew M. Intlekofer,Jay Patel,Andrei V. Krivstov,Garrett M. Frampton,Lauren Young,Shan Zhong,Mark Bailey,Jared White,Steven Roels,Jason Deffenbaugh,Alex Fichtenholtz,Tim Brennan,Margaret Rosenzweig,Kimberly Pelak,Kristina M. Knapp,Kristina W. Brennan,Amy Donahue,Geneva Young,Lazaro Garcia,Selmira T. Beckstrom,Mandy Zhao,Emily White,Vera Banning,Jamie Buell,Kiel Iwanik,Jeffrey S. Ross,Deborah Morosini,Anas Younes,Alan M. Hanash,Elisabeth Paietta,Kathryn G. Roberts,Charles G. Mullighan,Ahmet Dogan,Scott A. Armstrong,Tariq I. Mughal,Tariq I. Mughal,Jo Anne Vergilio,Elaine LaBrecque,Rachel L. Erlich,Christine Vietz,Roman Yelensky,Philip J. Stephens,Vincent A. Miller,Marcel R.M. van den Brink,Geoff Otto,Doron Lipson,Ross L. Levine +51 more
TL;DR: A novel next-generation sequencing-based assay to identify all classes of genomic alterations using archived formalin-fixed paraffin-embedded blood and bone marrow samples with high accuracy in a clinically relevant time frame is developed, which increases the ability to identify clinically relevant genomic alterations with therapeutic relevance.
Journal ArticleDOI
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Jeffrey S. Ross,Kai Wang,Juliann Chmielecki,Adrienne Johnson,Jacob Chudnovsky,Roman Yelensky,Doron Lipson,Siraj M. Ali,Julia A. Elvin,Jo Anne Vergilio,Steven Roels,Vincent A. Miller,Brooke N. Nakamura,Adam Gray,Michael K. Wong,Philip J. Stephens +15 more
TL;DR: BRAF fusions are rare driver alterations in a wide variety of malignant neoplasms, but enriched in Spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers.
Journal ArticleDOI
Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
Travis A. Clark,Jon Chung,Mark Kennedy,Jason D. Hughes,Niru Chennagiri,Daniel S. Lieber,Bernard Fendler,Lauren Young,Mandy Zhao,Michael Coyne,Virginia Breese,Geneva Young,Amy Donahue,Dean Pavlick,Alyssa Tsiros,Tim Brennan,Shan Zhong,Tariq I Mughal,Mark Bailey,Jie He,Steven Roels,Garrett M. Frampton,Jill M. Spoerke,Steven Gendreau,Mark R. Lackner,Erica B. Schleifman,Eric Peters,Jeffrey S. Ross,Siraj M. Ali,Vincent A. Miller,Jeffrey P. Gregg,Philip J. Stephens,Allison Welsh,Geoff Otto,Doron Lipson +34 more
TL;DR: High-sequencing coverage and molecular barcode–based error detection enabled accurate detection of genomic alterations, including short variants (base substitutions, short insertions/deletions) and genomic re-arrangements at low allele frequencies (AFs), and copy number amplifications in FoundationACT.